FIFTH AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT UC Agreement Control No. 2006-04-0085Exclusive License Agreement Uc Agreement • February 26th, 2016 • Medivation, Inc. • Pharmaceutical preparations
This Fifth Amendment to Exclusive License Agreement (“Fifth Amendment”), dated as of October 21, 2009, is made by and among The Regents of the University of California, a California corporation (“The Regents”), Medivation, Inc., a Delaware corporation (“Medivation”), and Medivation Prostate Therapeutics, Inc., a Delaware corporation and subsidiary of Medivation (“MPT”) (Medivation and MPT together “Licensee”).
Fourth Amendment To Exclusive License Agreement Between The Regents of the University of California and Medivation, Inc and Medivation Prostate Therapeutics, Inc For UC Agreement Control No. 2006-04-0085Exclusive License Agreement • February 26th, 2016 • Medivation, Inc. • Pharmaceutical preparations
This Fourth Amendment to Exclusive License Agreement (“Fourth Amendment”), dated as of July 17, 2007, is made by and among The Regents of the University of California, a California corporation (“The Regents”), Medivation, Inc., a Delaware corporation (“Medivation”), and Medivation Prostate Therapeutics, Inc., a Delaware corporation and subsidiary of Medivation (“MPT”) (Medivation and MPT together “Licensee”).
FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT UC Agreement Control No. 2006-04-0085Exclusive License Agreement Uc Agreement • February 26th, 2016 • Medivation, Inc. • Pharmaceutical preparations
This First Amendment to Exclusive License Agreement (this “Amendment”), dated as of November 4, 2005, is made by and among The Regents of the University of California, a California corporation (“The Regents”), Medivation, Inc., a Delaware corporation (“Medivation”), and Medivation Prostate Therapeutics, Inc., a Delaware corporation and subsidiary of Medivation (“MPT”)
SUPPLEMENTAL AGREEMENT REGARDING CDX AGREEMENT AND COLLABORATION AGREEMENT AND SIXTH AMENDMENT TO COLLABORATION AGREEMENTSupplemental Agreement • February 26th, 2016 • Medivation, Inc. • Pharmaceutical preparations
This Supplemental Agreement Regarding CDx Agreement and Collaboration Agreement And Sixth Amendment to Collaboration Agreement (this “Supplemental Agreement”) is entered into as of January 6, 2016 (the “Effective Date”) by and among Medivation, Inc., a Delaware corporation having offices located at 525 Market Street, 36th Floor, San Francisco, CA 94105, United States, its wholly owned subsidiary Medivation Prostate Therapeutics, Inc., a Delaware corporation having offices located at [the same location] (such entities, collectively, “Medivation”), Astellas Pharma Inc., a Japanese corporation having offices located at 2-5-1, Nihonbashi Honcho, Chuo Ku, Tokyo 103- 8411, Japan (“API”) and its indirect wholly owned subsidiary Astellas US LLC, a Delaware limited liability company having office located at 1 Astellas Way, Northbrook, Illinois 60062, United States (collectively with API, “Astellas”). Medivation and Astellas are sometimes referred to herein individually as a “Party” and collecti
THIRD AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT UC Agreement Control No. 2006-04-0085Exclusive License Agreement Uc Agreement • February 26th, 2016 • Medivation, Inc. • Pharmaceutical preparations
This Third Amendment to Exclusive License Agreement (“Third Amendment”), dated as of June 12, 2006, is made by and among The Regents of the University of California, a California corporation (“The Regents”), Medivation, Inc., a Delaware corporation (“Medivation”), and Medivation Prostate Therapeutics, Inc., a Delaware corporation and subsidiary of Medivation (“MPT”) (Medivation and MPT together “Licensee”).
AMENDMENT NO. 1 Dated as of November 13, 2015 to AMENDED AND RESTATED CREDIT AGREEMENT Dated as of October 23, 2015Credit Agreement • February 26th, 2016 • Medivation, Inc. • Pharmaceutical preparations • New York
THIS AMENDMENT NO. 1 (this “Amendment”) is made as of November 13, 2015 by and among Medivation, Inc., a Delaware corporation (the “Borrower”), the financial institutions listed on the signature pages hereof and JPMorgan Chase Bank, N.A., as Administrative Agent (the “Administrative Agent”), under that certain Amended and Restated Credit Agreement dated as of October 23, 2015 by and among the Borrower, the Lenders and the Administrative Agent (as amended, restated, supplemented or otherwise modified from time to time, the “Credit Agreement”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings given to them in the Credit Agreement.
SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT UC Agreement Control No. 2006-04-0085Exclusive License Agreement Uc Agreement • February 26th, 2016 • Medivation, Inc. • Pharmaceutical preparations
This Second Amendment to Exclusive License Agreement (“Second Amendment”), dated as of May 8 , 2006, is made by and among The Regents of the University of California, a California corporation (“The Regents”), Medivation, Inc., a Delaware corporation (“Medivation”), and Medivation Prostate Therapeutics, Inc., a Delaware corporation and subsidiary of Medivation (“MPT”).
